Cardiac Progenitor Cells Engineered With βARKct Have Enhanced β-Adrenergic Tolerance
Cardiac Progenitor Cells Engineered With βARKct Have Enhanced β-Adrenergic Tolerance
复制标题
DOI:
10.1038/mt.2013.200
复制
发表时间:
2014-01-01
影响因子:
12.4
通讯作者:
Sussman, Mark A.
中科院分区:
文献类型:
--
作者:
Khan, Mohsin;Mohsin, Sadia;Sussman, Mark A.
Stem cell survival and retention in myocardium after injury following adoptive transfer is low. Elevated catecholamine levels coinciding with myocardial injury adversely affect cardiac progenitor cell (CPC) survival. The G protein-coupled receptor kinase 2 (GRK2)-derived inhibitory peptide, beta ARKct, enhance myocyte contractility, survival, and normalize the neurohormonal axis in failing heart, however salutary effects of beta ARKct on CPC survival and proliferation are unknown. Herein, we investigated whether the protective effects of beta ARKct expression seen in the failing heart relate to CPCs. Modified CPCs expressing beta ARKct enhanced AKT/eNOS signaling through protective beta 2-adrenergic receptors (beta 2-ARs). In addition, to the actions of beta ARKct expression on beta 2- AR signaling, pharmacologic inhibition of GRK2 also increased beta 2-AR signaling in nonengineered CPCs (lacking beta ARKct) but had limited effects in beta ARKct engineered CPCs providing evidence for the strength of the beta ARKct in inhibiting GRK2 in these cells. Increased proliferation and metabolic activity were observed in beta ARKct-engineered CPCs following catecholamine stimulation indicating improved adrenergic tolerance. beta ARKct modification of CPCs increased survival and proliferation following adoptive transfer in an acute myocardial infarction model concomitant with increased expression of beta-AR. Thus, beta ARKct engineering of CPCs promotes survival and proliferation of injected cells following myocardial infarction, which includes improved beta-adrenergic tolerance essential for stem cell survival.